Biopharmaceutical company DiscGenics has raised $50 million in a Series C funding round, according to an Aug. 25 news release.
Biologics
The Steadman Philippon Research Institute in Vail, Colo., has received a grant from the National Institutes of Health to study the use of bone marrow stem cells to delay osteoarthritis in the knee.
The FDA has cleared Genentech's Evrysdi drug for spinal muscular atrophy in adults and children 2 months of age and older, according to an Aug. 10 announcement.
More than 6,000 members have joined the Biologic Association within the first six months of its website launch.
Since the beginning of the year, Becker's Spine Review has reported on eight orthobiologic and regenerative medicine companies that have launched new products, received FDA clearances and demonstrated favorable outcomes in clinical trials:
Advertisement
Orthobiologics company Cerapedics received FDA approval to reduce the number of patients required for its P-15L bone graft clinical trial.
Spinal implant developer Spine Wave has launched its Tempest Allograft Bone Matrix, according to a July 14 news release.
Orthobiologics company Bioventus said July 16 that it has invested $15 million in CartiHeal and agreed on an option structure to acquire the company pending approval of its Agili-C implant.
Orthobiologics company Baxter has received FDA clearance July 9 for its Altapore Shape Bioactive Bone Graft for spine surgery, according to Biospace.
Regenerative medicine company Aziyo Biologics on June 29 launched OsteoGro V, a viable cell bone matrix to assist with bone repair.